Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oxidative Stress in Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04512547
Recruitment Status : Not yet recruiting
First Posted : August 13, 2020
Last Update Posted : September 25, 2020
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Bastiaan Driehuys, Duke University

Brief Summary:
40% of all asthma patients in the US are obese. Obese asthmatics have more severe disease than lean asthmatics and do not respond as well to conventional anti-inflammatory therapies. This proposal will utilize 3D functional imaging with 129XeMRI and single cell RNA sequencing to study mechanisms driving regional airway remodeling and fibrosis in obese asthma subjects and in preclinical models of obese asthma.

Condition or disease Intervention/treatment Phase
Asthma Obesity Drug: Hyperpolarized 129XeMRI Phase 2

Detailed Description:

ABSTRACT

Obesity, a major comorbidity and a potential modulator of asthma, affects nearly 40% of asthmatics in the U.S., and increases its severity. Obese asthmatics do not respond as well to conventional anti-inflammatory therapies and new biologics targeting asthma are less effective in obese asthmatics compared to lean. Very little research has been conducted in obese animals or obese asthmatics, resulting in a major knowledge deficit.

A key feature of asthma is airway remodeling and fibrosis, broadly defined as a change in distribution, thickness, composition, mass or volume of structural components of the airway wall of patients relative to healthy patients. Airway remodeling is difficult to diagnose in obese patients as mechanical changes in chest wall compliance can contribute to the physiological changes seen. Classically, evidence of airway remodeling and fibrosis are revealed as fixed airway obstruction on spirometry. However, spirometry is not only insensitive to the peripheral airways, where airway remodeling occurs, but is fundamentally incapable of localizing the sites of remodeling and fibrosis. Thus, a critical research limitation in the study of airway remodeling and fibrosis in asthma is defining regions of disease activity to explore disease-specific mechanisms. To understand the nature of airway remodeling and fibrosis in obese asthma and to rapidly screen for novel therapies requires translation between preclinical models and patients, while using advanced imaging. Recent work in asthma using 3D functional imaging with 129Xe MRI has revealed the location of both reversible and fixed ventilation defects (defined based on bronchodilator responsivity). Several studies suggest that fixed defects represent sites of airway remodeling and fibrosis, but to date, this has been inferred indirectly from sputum analyses and CT scans. The central hypothesis is that sites of abnormal ventilation on 129XeMRI represent areas of airway remodeling and fibrosis and are enriched with fibroblasts that are invasive, proliferative and fibrogenic. It is further hypothesized that regional alterations in oxidant stress driving the production of transforming growth factor-beta (TGF-β) direct pro-remodeling fibroblast functions. Lastly, it is hypothesized that 129XeMRI will be a sensitive and specific biomarker of airway remodeling and fibrosis in obese asthmatics and rat models of obese asthma. By leveraging our excellence in clinical asthma, bronchoscopy, and translational expertise in cell function/signaling and 3D MR imaging in both patients and animal models, both ex vivo cell-specific mechanistic studies and in vivo animal model studies will be conducted to uncover the mechanisms of molecular and cellular function through the following Specific Aims: Aim 1) Identify the pathology, structural cell profile (airway fibroblast and epithelial cell) and redox status corresponding to regional areas of fixed and reversible post-bronchodilator defects (BD) in obese asthmatics; 2) Define the cellular requirement for redox-mediated TGF-β signaling between airway epithelial cells and fibroblasts driving regional remodeling in obese asthma; 3) Develop non-invasive 3D imaging techniques to assess airway regional remodeling in experimental rodent models of obese asthma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Diagnostic
Official Title: Oxidative Stress and Regional Airway Remodeling and Fibrosis in Obese Asthma
Estimated Study Start Date : October 1, 2020
Estimated Primary Completion Date : January 1, 2025
Estimated Study Completion Date : January 1, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: Obese Asthmatics
Obese patients that come to Duke that have been diagnosed with Asthma will be approached.
Drug: Hyperpolarized 129XeMRI
Images obtained using 129XeMRI will be obtained on both obese asthmatic and non-asthmatics

Active Comparator: Obese Non-Asthmatics
The obese non-asthmatics will be collected from an IRB pre-approved Healthy Volunteer Data Repository.
Drug: Hyperpolarized 129XeMRI
Images obtained using 129XeMRI will be obtained on both obese asthmatic and non-asthmatics




Primary Outcome Measures :
  1. Percent trichrome or elastic or fiber staining between fixed and reversible airway segments in obese asthma groups (early onset, late onset) and non-asthma controls will be determined. [ Time Frame: Up to 6 weeks ]
  2. Percent neutrophils in peripheral blood in obese and lean asthmatics will be determined. [ Time Frame: Up to 6 weeks ]
  3. Percent eosinophils in peripheral blood in obese and lean asthmatics will be determined. [ Time Frame: Up to 6 weeks ]
  4. Percent change in 3-Nitrotyrosine production by airway epithelial cells harvested from obese and lean asthmatics and non-asthmatic obese controls will be determined. [ Time Frame: Baseline, visit 1 (one week +/- 7 day), visit 2 (one week +/- 7 day), visit 3 (one week +/- 7 day) ]
  5. Percent change in H202 production by airway epithelial cells harvested from obese and lean asthmatics and non-asthmatic obese controls will be determined. [ Time Frame: Baseline, visit 1 (one week +/- 7 day), visit 2 (one week +/- 7 day), visit 3 (one week +/- 7 day) ]
  6. Leptin stimulated human airway fibroblast invasiveness will be determined by counting mean numbers of invading fibroblasts in obese and lean asthmatics and non-asthmatic obese controls. [ Time Frame: Up to 6 weeks ]
  7. Percent change in intracellular ROS production by airway fibroblasts will be assessed using flow cytometry. [ Time Frame: Baseline, visit 1 (one week +/- 7 day), visit 2 (one week +/- 7 day), visit 3 (one week +/- 7 day) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Asthma Cohort INCLUSION

  • Adequate completion of informed consent process with written documentation
  • Male and female patients, 18 - 65 years old, inclusive
  • Physician diagnosis of asthma for > 1 year
  • Able to perform reproducible spirometry according to ATS criteria
  • Post-bronchodilator FEV1 ≥ 60% of predicted at Visit 0
  • All racial/ethnic backgrounds may participate
  • BMI ≥ 30 kg/m2
  • Regular treatment with ICS or ICS/LABA and/or LAMA combination medication for at least 3 months; on a stable dose for the 4 weeks prior to Visit 0
  • Smoking history <10 pack years and no smoking in the last 3 months
  • Late onset asthma: Age of asthma onset (diagnosis) ≥12 years;
  • FeNO < 25 ppb at Visit 0
  • Negative allergen skin test
  • Early onset asthma: Age of asthma onset (diagnosis) <12 years
  • FeNO ≥ 25 ppb at Visit 0
  • Positive allergen skin test

Non-Asthma Cohort INCLUSION

  • No history of asthma or other chronic lung diseases
  • Male and female patients, 18 - 65 years old, inclusive
  • Not currently smoking or using other forms of tobacco-related products (including vaping)
  • Smoking history <10 pack years and no smoking in the past 3 months
  • FEV1 > 80% of predicted and FEV1/FVC > lower limit of normal.
  • Ability to sign consent
  • BMI ≥ 30 kg/m2
  • Negative allergen skin test

Additional INCLUSION Criteria for MRI

  • Outpatients of either gender, age > 18
  • Willing and able to give informed consent and adhere to visit/protocol schedules. (Consent must be given before any study procedures are performed.)
  • Women of childbearing potential must have a negative urine pregnancy test prior to MRI.

EXCLUSION Criteria

Asthma Cohort EXCLUSION:

  • Respiratory tract infection within the 4 weeks prior to Visit 0
  • Oral or systemic corticosteroid burst (for any indication) within the 4 weeks prior to Visit 0. One-time doses, such as intra-articular injections into a shoulder or knee joint, require a 4- week washout prior to Visit 0
  • Asthma-related ER visit within the previous 4 weeks of Visit 0
  • History of ICU admission/intubation due to asthma in the past 1 year
  • Three or more asthma exacerbations requiring treatment with systemic corticosteroids in the past year consistent with severe asthma
  • Asthma exacerbation requiring systemic corticosteroids within the 4 weeks prior to Visit 0
  • Significant concomitant medical illness, including (but not limited to) heart disease, cancer, uncontrolled diabetes, other chronic lung diseases
  • Chronic renal failure (creatinine > 2.0) at Visit 0
  • Positive urine pregnancy test at Visit 0 or at any time during the study
  • Untreated sleep apnea
  • Participation in an intervention study (including, bronchoscopy) or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study
  • Unable or unlikely to complete study assessments in the opinion of the Investigator
  • Study intervention poses undue risk to patient in the opinion of the Investigator
  • History of bronchial thermoplasty

Non-Asthma Cohort EXCLUSION:

  • Respiratory tract infection within the 4 weeks prior to Visit 0 Oral or systemic corticosteroid burst (for any indication) within the 4 weeks prior to Visit 0. One-time doses, such as intra-articular injections into a shoulder or knee joint, require a 4-week washout prior to Visit 0
  • Significant concomitant medical illness, including (but not limited to) heart disease, cancer, uncontrolled diabetes, other chronic lung diseases
  • Chronic renal failure (creatinine > 2.0) at Visit 0
  • Positive urine pregnancy test at Visit 0 or at any time during the study
  • Untreated sleep apnea
  • Participation in an intervention study (including bronchoscopy) or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study
  • Unable or unlikely to complete study assessments in the opinion of the Investigator
  • Study intervention poses undue risk to patient in the opinion of the Investigator

Additional EXCLUSION Criteria for MRI

  • Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
  • Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine, shoulder circumference >140 cm*.) *This measurement is not an absolute as it can vary based on weight distribution.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04512547


Contacts
Layout table for location contacts
Contact: Antoinette Santoro, MS, BSRT, RRT 919-479-0731 maria.santoro@duke.edu
Contact: Catherine Foss, BS, RRT, RPFT, CCRC 919-613-7627 catherine.foss@duke.edu

Sponsors and Collaborators
Bastiaan Driehuys
National Institutes of Health (NIH)
Investigators
Layout table for investigator information
Principal Investigator: Loretta Que, MD Duke
Layout table for additonal information
Responsible Party: Bastiaan Driehuys, Professor of Medicine, Duke University
ClinicalTrials.gov Identifier: NCT04512547    
Other Study ID Numbers: Pro00104900
First Posted: August 13, 2020    Key Record Dates
Last Update Posted: September 25, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases